Kinfo
Lixte Biotechnology Holdings Inc. logo

Lixte Biotechnology Holdings Inc.

LIXTNASDAQHealthcare·US · USD
$8.08
+0.89 (+12.38%)
Close · 2026-06-29

Price

Key statistics

Valuation
Market cap125.01M USD
Enterprise value88.07M USD
Trailing P/E-6.41
Forward P/E0.00
PEG ratio0.17
Price / sales0.00
Price / book10.53
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-64.50%
Return on equity-140.99%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income-7.31M USD
Diluted EPS-$1.15
Rev. growth (YoY)0.00%
Balance sheet
Total cash3.25M USD
Total debt1.06M USD
Debt / equity11.52
Current ratio2.78
Book value / share$0.68
Cash flow (TTM)
Operating cash flow-4.33M USD
Levered free cash flow-2.33M USD
Shares & price
Shares outstanding11.63M
Float11.07M
Held by institutions5.57%
Beta1.28
50-day MA$5.50
200-day MA$4.27
52-week high$8.17
52-week low$0.68
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-01-170.380.34−10.53%2025-11-260.56-0.62−210.71%2025-10-270.540.54+0.00%
About Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc. is a biotechnology company specializing in the research and development of treatments aimed at addressing various forms of cancer and other serious diseases. The primary function of Lixte is to innovate in the field of drug development by focusing on novel compounds that can serve as potential therapeutics. Notably, the company concentrates on identifying and developing small molecule inhibitors that target specific pharmacological pathways involved in cancer progression and other diseases. Lixte operates primarily within the biotechnology and pharmaceutical sectors, holding significance for its contribution to potentially groundbreaking cancer therapies. By focusing on a niche market in oncology and the broader healthcare industry, Lixte Biotechnology Holdings Inc. plays a critical role in advancing scientific research and offering new hope in the fight against complex diseases. Its activities exemplify the intersection of cutting-edge science and the quest for effective clinical solutions in a highly dynamic and innovative sector.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Geordan G. Pursglove
Employees
3
Headquarters
Boca Raton, FL, United States
Website
lixte.com

Frequently asked questions about Lixte Biotechnology Holdings Inc.